WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

FDA Regulatory, Healthcare, and Consumer Products

Open PDF
  • Comprehensive Consumer Products Experience

    Wilson Sonsini can assist consumer product companies throughout the entire product life cycle--including stages in which they're introducing new products and services into the domestic U.S. and global marketplaces.

Wilson Sonsini represents life sciences, healthcare, and consumer products companies in matters involving regulation by the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), the Office of the Inspector General, and other federal and state consumer protection agencies.

Wilson Sonsini's Comprehensive Regulatory Practice

Wilson Sonsini’s attorneys focus on food and drug law and regulatory policy governing the regulation of a broad range of life sciences products—from pharmaceutical and biotechnology products to medical devices and dietary supplements. They also focus on laws and regulations pertaining to consumer products, including those administered by the FTC, the U.S. Consumer Product Safety Commission (CPSC), and various state and local regulatory agencies responsible for health and safety.

The firm’s clients in this area include U.S. and foreign manufacturers, distributors, retailers, and importers of regulated products.

FDA Expertise

Our attorneys advise clients of all sizes, and at all stages of development, on critical aspects of FDA regulation and healthcare matters. For example, they help early-stage and maturing life science companies obtain and maintain the necessary regulatory approvals from the FDA and other government agencies. They also counsel companies on the various regulatory pathways to commercialization and clinical development. The team helps place biopharmaceutical, digital health, and medical device clients in a favorable position to clear regulatory  hurdles, secure timely approvals, and maintain those approvals.

Given the firm’s nexus to companies behind next-generation products and innovative technologies, we commonly help clients with novel medical technologies develop FDA approval and clearance strategies for reaching the market, including combination drug/device products, as well as prepare marketing applications, requests for product designation, and Investigational Device Exemption applications. For example, we counsel life science clients on all aspects of post-approval/clearance requirements such as product advertising, adverse event reporting, and Quality System Regulation (QSR) compliance. We also advise clients on matters related to Medicare reimbursement of products regulated by the FDA.

Healthcare Fraud and Investigations Expertise

The firm’s team also devotes significant time to counseling regulated companies on extensive state and federal healthcare laws, including broad-based fraud and abuse laws, the Anti-Kickback Statute, the False Claims Act, the Sunshine Act, patient privacy statutes, and equivalent state laws. We also have substantial experience assisting clients engaged in internal/board of directors investigations and government inquiries, including, for example, responses to Office of Inspector General (OIG) and U.S. Department of Justice (DOJ) subpoenas.

Advertising and Marketing Expertise

Finally, Wilson Sonsini's team also counsels clients on all aspects of the marketing and promotion of products, including print and online advertising and promotion, and labeling.

Experience with a Broad Range of Life Sciences, Healthcare, and Consumer Products

Our attorneys have first-hand experience representing manufacturers and distributors of a wide range of life sciences, healthcare, and consumer product categories. Examples include:

  • agriculture and food
  • biologics
  • pharmaceuticals (including OTCs)
  • medical devices
  • digital health
  • dietary supplements
  • vitamins and minerals
  • cosmetics

Our Integrated and Comprehensive Approach

In addition to comprehensive services that help clients in matters related to regulatory approval, we also have an integrated approach to assisting companies throughout their product cycles. Wilson Sonsini's team brings its experience across corporate transactions, intellectual property, regulatory, and litigation areas to bear to assist clients at all stages of growth, from formation to global public company.

Overview

Wilson Sonsini represents life sciences, healthcare, and consumer products companies in matters involving regulation by the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), the Office of the Inspector General, and other federal and state consumer protection agencies.

Wilson Sonsini's Comprehensive Regulatory Practice

Wilson Sonsini’s attorneys focus on food and drug law and regulatory policy governing the regulation of a broad range of life sciences products—from pharmaceutical and biotechnology products to medical devices and dietary supplements. They also focus on laws and regulations pertaining to consumer products, including those administered by the FTC, the U.S. Consumer Product Safety Commission (CPSC), and various state and local regulatory agencies responsible for health and safety.

The firm’s clients in this area include U.S. and foreign manufacturers, distributors, retailers, and importers of regulated products.

FDA Expertise

Our attorneys advise clients of all sizes, and at all stages of development, on critical aspects of FDA regulation and healthcare matters. For example, they help early-stage and maturing life science companies obtain and maintain the necessary regulatory approvals from the FDA and other government agencies. They also counsel companies on the various regulatory pathways to commercialization and clinical development. The team helps place biopharmaceutical, digital health, and medical device clients in a favorable position to clear regulatory  hurdles, secure timely approvals, and maintain those approvals.

Given the firm’s nexus to companies behind next-generation products and innovative technologies, we commonly help clients with novel medical technologies develop FDA approval and clearance strategies for reaching the market, including combination drug/device products, as well as prepare marketing applications, requests for product designation, and Investigational Device Exemption applications. For example, we counsel life science clients on all aspects of post-approval/clearance requirements such as product advertising, adverse event reporting, and Quality System Regulation (QSR) compliance. We also advise clients on matters related to Medicare reimbursement of products regulated by the FDA.

Healthcare Fraud and Investigations Expertise

The firm’s team also devotes significant time to counseling regulated companies on extensive state and federal healthcare laws, including broad-based fraud and abuse laws, the Anti-Kickback Statute, the False Claims Act, the Sunshine Act, patient privacy statutes, and equivalent state laws. We also have substantial experience assisting clients engaged in internal/board of directors investigations and government inquiries, including, for example, responses to Office of Inspector General (OIG) and U.S. Department of Justice (DOJ) subpoenas.

Advertising and Marketing Expertise

Finally, Wilson Sonsini's team also counsels clients on all aspects of the marketing and promotion of products, including print and online advertising and promotion, and labeling.

Experience with a Broad Range of Life Sciences, Healthcare, and Consumer Products

Our attorneys have first-hand experience representing manufacturers and distributors of a wide range of life sciences, healthcare, and consumer product categories. Examples include:

  • agriculture and food
  • biologics
  • pharmaceuticals (including OTCs)
  • medical devices
  • digital health
  • dietary supplements
  • vitamins and minerals
  • cosmetics

Our Integrated and Comprehensive Approach

In addition to comprehensive services that help clients in matters related to regulatory approval, we also have an integrated approach to assisting companies throughout their product cycles. Wilson Sonsini's team brings its experience across corporate transactions, intellectual property, regulatory, and litigation areas to bear to assist clients at all stages of growth, from formation to global public company.

Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
News Articles
Jodi Daniel Quoted by KFF Health News and CNN on Healthcare Privacy Concerns
Wilson Sonsini partner Jodi Daniel was recently quoted in a KFF Health News article, which was also featured by CNN. The piece, titled "Trump’s Personnel Agency Is Asking for Federal Workers’ Medical Records," explores the Trump administration's notice regarding access to medical records of federal workers, retirees, and their families. The proposal has raised concerns about whether the collection meets requirements under the HIPAA privacy rules, which only allows health plans to disclose individually identifiable health information for limited purposes and even then only the minimum necessary. Concerns have also been raised about the Office of Personnel Management (OPM) having access to large amounts of health information, which would no longer be subject to HIPAA. Jodi, who played a pivotal role in shaping the legal framework for the HIPAA privacy rules over 20 years ago, commented, “The language in it [the OPM notice] seems quite broad and encompasses potentially a lot of information and data and is light on justification."
Alerts
FTC Announcement of Healthcare Task Force Coincides with Joint DOJ/FTC Appearance at ONC Annual Meeting
Two recent developments suggest that enforcers are poised to grapple with antitrust concerns in health tech, signaling an escalation of scrutiny into Information Blocking1 tactics that have persisted despite U.S. Department of Health and Human Services (HHS) rules and regulations designed to curtail such practices. Stakeholders and industry participants should be prepared for potential outreach.
Alerts
New FDA Draft Guidance Clarifies Three-Year Exclusivity for New Clinical Investigations
Key Takeaways
Alerts
Congress Reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and Clarifies Orphan Drug Exclusivity
Key Takeaways
Alerts
2026 Antitrust Year in Preview
Last year was a landmark in the development of antitrust law. Enforcers, legislators, and private parties grappled with the fundamental shift represented by artificial intelligence (AI) technologies, the resolution of important digital technology antitrust cases, and significant divergence in policy across a presidential administration transition. The changes will not stop in 2026. In this preview, we focus on several economic sectors that were most impacted by developments in antitrust law in 2025 to identify the trends that will drive governmental and private activity in antitrust in 2026.
View All
Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
News Articles
Jodi Daniel Quoted by KFF Health News and CNN on Healthcare Privacy Concerns
Wilson Sonsini partner Jodi Daniel was recently quoted in a KFF Health News article, which was also featured by CNN. The piece, titled "Trump’s Personnel Agency Is Asking for Federal Workers’ Medical Records," explores the Trump administration's notice regarding access to medical records of federal workers, retirees, and their families. The proposal has raised concerns about whether the collection meets requirements under the HIPAA privacy rules, which only allows health plans to disclose individually identifiable health information for limited purposes and even then only the minimum necessary. Concerns have also been raised about the Office of Personnel Management (OPM) having access to large amounts of health information, which would no longer be subject to HIPAA. Jodi, who played a pivotal role in shaping the legal framework for the HIPAA privacy rules over 20 years ago, commented, “The language in it [the OPM notice] seems quite broad and encompasses potentially a lot of information and data and is light on justification."
Alerts
FTC Announcement of Healthcare Task Force Coincides with Joint DOJ/FTC Appearance at ONC Annual Meeting
Two recent developments suggest that enforcers are poised to grapple with antitrust concerns in health tech, signaling an escalation of scrutiny into Information Blocking1 tactics that have persisted despite U.S. Department of Health and Human Services (HHS) rules and regulations designed to curtail such practices. Stakeholders and industry participants should be prepared for potential outreach.
Alerts
New FDA Draft Guidance Clarifies Three-Year Exclusivity for New Clinical Investigations
Key Takeaways
Alerts
Congress Reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and Clarifies Orphan Drug Exclusivity
Key Takeaways
Alerts
2026 Antitrust Year in Preview
Last year was a landmark in the development of antitrust law. Enforcers, legislators, and private parties grappled with the fundamental shift represented by artificial intelligence (AI) technologies, the resolution of important digital technology antitrust cases, and significant divergence in policy across a presidential administration transition. The changes will not stop in 2026. In this preview, we focus on several economic sectors that were most impacted by developments in antitrust law in 2025 to identify the trends that will drive governmental and private activity in antitrust in 2026.
View All
Affiliated Programs
Privacy, AI & the Future of HIPAA with the Former Founding Director of ONC
Join Digital Health partner Jodi Daniel for her upcoming discussion with Second Opinion Media’s Chrissy Farr.
Speaking Engagements
AI at the FDA in HealthTech: Rules, Risks, and the Road Ahead
Join Wilson Sonsini partner Eva Yin on May 13, 2026, as she and fellow panelists participate in a virtual briefing on the intersection of AI and HealthTech at the FDA. The webinar—co-sponsored by Wilson Sonsini, HSBC Innovation Banking, and Healthcare Innovation Catalysts—will offer practical and real-time insights in four areas: the FDA's framework for AI health tech, regulated health tech in practice, legal risk in the gray zone, and the global road ahead.
Affiliated Programs
NSF AHeAD Center Planning Meeting
Wilson Sonsini partner Eva Yin will participate in a planning meeting on artificial intelligence and healthcare hosted by the National Science Foundation AHeAD Center, taking place May 13, 2026, at the University of Florida’s Straughn Center in Gainesville. The meeting is a collaborative effort among the University of Florida, Georgia Tech, Tulane University, and the University of Louisiana at Lafayette.
Affiliated Programs
Next-Level Health Systems Summit: Leading with AI
Wilson Sonsini is pleased to sponsor the Next-Level Health Systems Summit: Leading with AI. No doubt that AI is reshaping the healthcare landscape and it is already embedded in clinical workflows, infrastructure stacks, and executive decision-making. The question is no longer whether to adopt AI, but where it truly delivers value, where it creates friction, and how to navigate both the transformative potential and the operational realities it entails. 
Speaking Engagements
AHLA Health Care Transactions Conference
On April 15th Wilson Sonsini partner Andrea Linna will present on the panel “Representing the Founders, Investors, and Innovators of Healthcare AI: Venture Capital and Emerging Companies.” The session will explore the central role venture capital plays in bringing healthcare AI to market and the complex legal landscape that founders and investors must navigate.
WSGR Events
Your Annual Healthcare Regulatory Compliance Checkup: What Digital Health GCs Should Be Reviewing Right Now
Just like your annual physical, your compliance program needs a regular checkup. Join Wilson Sonsini partners Andrea Linna and Jodi Daniel for an examination of the issues digital health GCs should be monitoring right now to uncover gaps before they become something more serious.
View All
Events
Affiliated Programs
Privacy, AI & the Future of HIPAA with the Former Founding Director of ONC
Join Digital Health partner Jodi Daniel for her upcoming discussion with Second Opinion Media’s Chrissy Farr.
Speaking Engagements
AI at the FDA in HealthTech: Rules, Risks, and the Road Ahead
Join Wilson Sonsini partner Eva Yin on May 13, 2026, as she and fellow panelists participate in a virtual briefing on the intersection of AI and HealthTech at the FDA. The webinar—co-sponsored by Wilson Sonsini, HSBC Innovation Banking, and Healthcare Innovation Catalysts—will offer practical and real-time insights in four areas: the FDA's framework for AI health tech, regulated health tech in practice, legal risk in the gray zone, and the global road ahead.
Affiliated Programs
NSF AHeAD Center Planning Meeting
Wilson Sonsini partner Eva Yin will participate in a planning meeting on artificial intelligence and healthcare hosted by the National Science Foundation AHeAD Center, taking place May 13, 2026, at the University of Florida’s Straughn Center in Gainesville. The meeting is a collaborative effort among the University of Florida, Georgia Tech, Tulane University, and the University of Louisiana at Lafayette.
Affiliated Programs
Next-Level Health Systems Summit: Leading with AI
Wilson Sonsini is pleased to sponsor the Next-Level Health Systems Summit: Leading with AI. No doubt that AI is reshaping the healthcare landscape and it is already embedded in clinical workflows, infrastructure stacks, and executive decision-making. The question is no longer whether to adopt AI, but where it truly delivers value, where it creates friction, and how to navigate both the transformative potential and the operational realities it entails. 
Speaking Engagements
AHLA Health Care Transactions Conference
On April 15th Wilson Sonsini partner Andrea Linna will present on the panel “Representing the Founders, Investors, and Innovators of Healthcare AI: Venture Capital and Emerging Companies.” The session will explore the central role venture capital plays in bringing healthcare AI to market and the complex legal landscape that founders and investors must navigate.
WSGR Events
Your Annual Healthcare Regulatory Compliance Checkup: What Digital Health GCs Should Be Reviewing Right Now
Just like your annual physical, your compliance program needs a regular checkup. Join Wilson Sonsini partners Andrea Linna and Jodi Daniel for an examination of the issues digital health GCs should be monitoring right now to uncover gaps before they become something more serious.
View All
Eva F. Yin
Partner
Seattle
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
  • Regulatory
View Profile
Daniel E. Orr
Senior Counsel
Dan Orr is senior counsel at Wilson Sonsini Goodrich & Rosati, where he brings an insider’s perspective to helping clients prevent and solve problems with the U.S. Food & Drug Administration. Dan, a former FDA regulatory counsel, has more than 20 years of experience concerning regulation of drugs, biologics, and medical devices.
  • FDA Regulatory, Healthcare, and Consumer Products
View Profile
Jodi Daniel
Partner
Washington, D.C.
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
  • Regulatory
View Profile
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.
  • Regulatory
View Profile
David M. Hoffmeister
Partner Emeritus
David represents pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients in the life sciences and healthcare industries.
  • Corporate
View Profile
Ralitza S. Dineva
Of Counsel
Palo Alto
Ralitza Dineva is Of Counsel in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on advising clients in connection with regulatory inquiries and internal investigations, white collar defense, and domestic and cross-border regulatory compliance counseling. She also has extensive experience handling complex commercial disputes, securities class actions, shareholder derivative lawsuits, and merger litigation before state and federal courts and in arbitration proceedings.
  • Litigation
View Profile
Lidia Niecko-Najjum
Of Counsel
Washington, D.C.
Lidia Niecko-Najjum is Of Counsel in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she provides strategic counseling on health care regulatory and policy matters. Lidia is a seasoned attorney and former nurse with over 15 years of legal and policy experience. Her practice is focused on data use, interoperability, information blocking, privacy and security, artificial intelligence, machine learning, digital therapeutics, and telehealth. Her representative clients include digital health companies, health information networks, health plans, health systems, and academic medical centers.
  • Regulatory
View Profile
Hale Melnick
Associate
Boulder
Hale Melnick is an associate in the privacy and cybersecurity group of Wilson Sonsini Goodrich & Rosati. He primarily advises digital health companies across a range of privacy, transactional, research, and health care regulatory issues. In particular, Hale leverages his expertise in HIPAA, the CCPA, the GDPR, and other state, national, and international privacy laws and regulations to provide early-stage companies with practical day-to-day support in the area of health care.
  • Data, Privacy, and Cybersecurity
View Profile
Seamus Taylor
Associate
Washington, D.C.
Seamus Taylor is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s digital health industry group and its healthcare practice. Seamus helps clients ranging from start-ups to publicly traded companies navigate the complex world of health law.
  • Regulatory
View Profile
People
Eva F. Yin
Partner
Seattle
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
  • Regulatory
View Profile
Daniel E. Orr
Senior Counsel
Dan Orr is senior counsel at Wilson Sonsini Goodrich & Rosati, where he brings an insider’s perspective to helping clients prevent and solve problems with the U.S. Food & Drug Administration. Dan, a former FDA regulatory counsel, has more than 20 years of experience concerning regulation of drugs, biologics, and medical devices.
  • FDA Regulatory, Healthcare, and Consumer Products
View Profile
Jodi Daniel
Partner
Washington, D.C.
Jodi Daniel is a nationally recognized leader in digital health law and policy, trusted by health care organizations and technology innovators to navigate the complex and dynamic regulatory landscape of digital health and wellness. With over 30 years of experience in healthcare innovation—including 15 years as a lawyer and senior policymaker at the U.S. Department of Health and Human Services (HHS)—Jodi leverages her extensive experience in digital health and health data to deliver strategic, practical advice to clients engaged in groundbreaking products and services that raise novel legal, policy, and ethical issues.
  • Regulatory
View Profile
Andrea Linna
Partner
Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.
  • Regulatory
View Profile
David M. Hoffmeister
Partner Emeritus
David represents pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients in the life sciences and healthcare industries.
  • Corporate
View Profile
Ralitza S. Dineva
Of Counsel
Palo Alto
Ralitza Dineva is Of Counsel in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on advising clients in connection with regulatory inquiries and internal investigations, white collar defense, and domestic and cross-border regulatory compliance counseling. She also has extensive experience handling complex commercial disputes, securities class actions, shareholder derivative lawsuits, and merger litigation before state and federal courts and in arbitration proceedings.
  • Litigation
View Profile
Lidia Niecko-Najjum
Of Counsel
Washington, D.C.
Lidia Niecko-Najjum is Of Counsel in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she provides strategic counseling on health care regulatory and policy matters. Lidia is a seasoned attorney and former nurse with over 15 years of legal and policy experience. Her practice is focused on data use, interoperability, information blocking, privacy and security, artificial intelligence, machine learning, digital therapeutics, and telehealth. Her representative clients include digital health companies, health information networks, health plans, health systems, and academic medical centers.
  • Regulatory
View Profile
Hale Melnick
Associate
Boulder
Hale Melnick is an associate in the privacy and cybersecurity group of Wilson Sonsini Goodrich & Rosati. He primarily advises digital health companies across a range of privacy, transactional, research, and health care regulatory issues. In particular, Hale leverages his expertise in HIPAA, the CCPA, the GDPR, and other state, national, and international privacy laws and regulations to provide early-stage companies with practical day-to-day support in the area of health care.
  • Data, Privacy, and Cybersecurity
View Profile
Seamus Taylor
Associate
Washington, D.C.
Seamus Taylor is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s digital health industry group and its healthcare practice. Seamus helps clients ranging from start-ups to publicly traded companies navigate the complex world of health law.
  • Regulatory
View Profile
Related Practices
  • Regulatory
  • Federal Trade Commission
  • Trademark and Advertising
  • Consumer Litigation
Related Industries
  • Consumer Products and Services
  • Biotech
  • Digital Health
  • Global Generics
  • Medical Devices
Recent Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Learn More
News Articles
Jodi Daniel Quoted by KFF Health News and CNN on Healthcare Privacy Concerns
Wilson Sonsini partner Jodi Daniel was recently quoted in a KFF Health News article, which was also featured by CNN. The piece, titled "Trump’s Personnel Agency Is Asking for Federal Workers’ Medical Records," explores the Trump administration's notice regarding access to medical records of federal workers, retirees, and their families. The proposal has raised concerns about whether the collection meets requirements under the HIPAA privacy rules, which only allows health plans to disclose individually identifiable health information for limited purposes and even then only the minimum necessary. Concerns have also been raised about the Office of Personnel Management (OPM) having access to large amounts of health information, which would no longer be subject to HIPAA. Jodi, who played a pivotal role in shaping the legal framework for the HIPAA privacy rules over 20 years ago, commented, “The language in it [the OPM notice] seems quite broad and encompasses potentially a lot of information and data and is light on justification."
Learn More
View All
Recent Events
Affiliated Programs
Privacy, AI & the Future of HIPAA with the Former Founding Director of ONC
Join Digital Health partner Jodi Daniel for her upcoming discussion with Second Opinion Media’s Chrissy Farr.
Learn More
Speaking Engagements
AI at the FDA in HealthTech: Rules, Risks, and the Road Ahead
Join Wilson Sonsini partner Eva Yin on May 13, 2026, as she and fellow panelists participate in a virtual briefing on the intersection of AI and HealthTech at the FDA. The webinar—co-sponsored by Wilson Sonsini, HSBC Innovation Banking, and Healthcare Innovation Catalysts—will offer practical and real-time insights in four areas: the FDA's framework for AI health tech, regulated health tech in practice, legal risk in the gray zone, and the global road ahead.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.